Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.02
- Piotroski Score 2.00
- Grade Neutral
- Symbol (TGTX)
- Company TG Therapeutics, Inc.
- Price $34.48
- Changes Percentage (10.69%)
- Change $3.33
- Day Low $31.42
- Day High $36.40
- Year High $36.50
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $23.00
- High Stock Price Target $55.00
- Low Stock Price Target $16.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.30
- Trailing P/E Ratio 52.83
- Forward P/E Ratio 52.83
- P/E Growth 52.83
- Net Income $12.67 M
Income Statement
Quarterly
Annual
Latest News of TGTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TG Therapeutics Inc (TGTX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
Adam Waldman expects BRIUMVI's market share in the anti-CD 20 market for MS to grow to the mid-50s or even 60% by 2025....
By Yahoo! Finance | 2 weeks ago -
Is TG Therapeutics, Inc. (TGTX) Set to Explode in 2025?
A list of 10 stocks set to explode in 2025 includes TG Therapeutics, Inc. and big tech companies. Nancy Tengler highlights big tech's strong market position and suggests investing in tech over traditi...
By Yahoo! Finance | 3 weeks ago -
TG Therapeutics Inc (TGTX): Short Seller Sentiment is Bearish
A list of the worst 52-week high stocks includes TG Therapeutics Inc. Despite positive results, the company faces high short interest due to concerns about drug competition and patent expiration. Fina...
By Yahoo! Finance | 2 months ago
